Terminal 14q32.33 deletion as a novel cause of agammaglobulinemia

被引:3
作者
Geier, Christoph B. [1 ]
Piller, Alexander [1 ]
Eibl, Martha M. [1 ,2 ]
Ciznar, Peter [3 ,4 ]
Ilencikova, Denisa [3 ,4 ,5 ]
Wolf, Hermann M. [1 ,6 ]
机构
[1] Immunol Outpatient Clin, Vienna, Austria
[2] Biomed Forsch GmbH, Vienna, Austria
[3] Comenius Univ, Fac Med, Dept Pediat, Bratislava, Slovakia
[4] Childrens Univ Hosp, Bratislava, Slovakia
[5] Kepler Univ Klinikum, Zentrum Med Genet, Linz, Austria
[6] Sigmund Freud Private Univ, Med Sch, Vienna, Austria
关键词
Primary immunodeficiency; Agammaglobulinemia; B-cell defect; Microdeletion; 14q32.33; PRIMARY ANTIBODY DEFICIENCIES; X-LINKED AGAMMAGLOBULINEMIA;
D O I
10.1016/j.clim.2017.07.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past decades, a pleiotropic spectrum of B-cell intrinsic defects leading to early onset agammaglobulinemia and absent B cells has been described. Herein we report terminal 14q32.33 deletion as a novel cause of agammaglobulinemia. We describe a 20-year old man with a 1 MB terminal 14q32.33 deletion resulting in a loss of the entire Immunoglobulin heavy chain gene region of chromosome 14. The patient presented with absent serum immunoglobulin levels and absent circulating B cells since age 2. The clinical picture was dominated by severe episodes of recurrent upper respiratory tract infections. In the literature, the most prevalent features of terminal 14q32.33 deletions include mental disability, facial malformation, hypotonia, seizures, and visual problems with retinal abnormalities. Neither increased susceptibility to infections nor agammaglobulinemia have been described as a manifestation of terminal 14q32.33 deletion. Thus, our findings expand the known clinical spectrum of terminal 14q32.33 deletion to include susceptibility to infections. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:41 / 45
页数:5
相关论文
共 18 条
[1]  
BRUTON OC, 1952, PEDIATRICS, V9, P722
[2]   Xenopus BTBD6 and Its Drosophila Homologue lute Are Required for Neuronal Development [J].
Bury, Frederic J. ;
Moers, Virginie ;
Yan, Jiekun ;
Souopgui, Jacob ;
Quan, Xiao-Jiang ;
De Geest, Natalie ;
Kricha, Sadia ;
Hassan, Bassem A. ;
Bellefroid, Eric J. .
DEVELOPMENTAL DYNAMICS, 2008, 237 (11) :3352-3360
[3]   Primary antibody deficiencies [J].
Durandy, Anne ;
Kracker, Sven ;
Fischer, Alain .
NATURE REVIEWS IMMUNOLOGY, 2013, 13 (07) :519-533
[4]   Plasma cell development: From B-cell subsets to long-term survival niches [J].
Fairfax, Kirsten A. ;
Kallies, Axel ;
Nutt, Stephen L. ;
Tarlinton, David M. .
SEMINARS IN IMMUNOLOGY, 2008, 20 (01) :49-58
[5]   Pathogenesis, Diagnosis, and Management of Primary Antibody Deficiencies and Infections [J].
Fried, Ari J. ;
Bonilla, Francisco A. .
CLINICAL MICROBIOLOGY REVIEWS, 2009, 22 (03) :396-414
[6]   A child with an inherited 0.31 Mb microdeletion of chromosome 14q32.33: Further delineation of a critical region for the 14q32 deletion syndrome [J].
Holder, J. Lloyd, Jr. ;
Lotze, Timothy E. ;
Bacino, Carlos ;
Cheung, Sau-Wai .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2012, 158A (08) :1962-1966
[7]   Patterns of Jagged1, Jagged2, delta-like 1 and delta-like 3 expression during late embryonic and postnatal brain development suggest multiple functional roles in progenitors and differentiated cells [J].
Irvin, DK ;
Nakano, I ;
Paucar, A ;
Kornblum, HI .
JOURNAL OF NEUROSCIENCE RESEARCH, 2004, 75 (03) :330-343
[8]   Characterization of novel Bruton's tyrosine kinase gene mutations in Central European patients with agammaglobulinemia [J].
Kristufek, Doris ;
Aspalter, Rosa Maria ;
Eibl, Martha Marianne ;
Wolf, Hermann Maximilian .
MOLECULAR IMMUNOLOGY, 2007, 44 (07) :1639-1643
[9]   Terminal 14q32.33 deletion: Genotype-phenotype correlation [J].
Maurin, M. -L. ;
Brisset, S. ;
Le Lorc'h, M. ;
Poncet, V. ;
Trioche, P. ;
Aboura, A. ;
Labrune, P. ;
Tachdjian, G. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2006, 140A (21) :2324-2329
[10]  
MEASE PJ, 1985, NEW ENGL J MED, V313, P758